References
- Donaldson JM, Kari C, Fragoso RC, et al. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther. 2009 Nov;8(22):2147–2152.
- Erster O, Thomas JM, Hamzah J, et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012 Aug 10;161(3):804–812.
- Thomas JM, Daugherty PS. Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries. Protein Sci. 2009 Oct;18(10):2053–2059.
- Daugherty PS, Stagliano NE, Thomas J, et al. Activatable binding polypeptides and methods of identification and use thereof. WO2009025846. 2009
- Polu KR, Lowman HB. Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther. 2014 Aug;14(8):1049–1053.
- Vasiljeva O, Hostetter DR, Moore SJ, et al. The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation. Biol Chem. 2019 Apr 22;400(8):965–977.
- Sevenich L, Joyce JA. Pericellular proteolysis in cancer. Genes Dev. 2014 Nov 1;28(21):2331–2347.
- Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov. 2010 Sep;9(9):690–701.
- Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006 Sep;;5(9):785–799.
- Deu E, Verdoes M, Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol. 2012 Jan 5;19(1):9–16.
- Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326–336.
- Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013 Oct 16;5(207):207ra144.
- Cieplak P, Strongin AY. Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond. Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1952–1963.
- Vandooren J, Geurts N, Martens E, et al. Zymography methods for visualizing hydrolytic enzymes. Nat Methods. 2013 Mar;10(3):211–220.
- LeBeau AM, Sevillano N, Markham K, et al. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015 Apr 1;75(7):1225–1235.
- LeBeau AM, Lee M, Murphy ST, et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93–98.
- Wong C, Mei L, Wong KR, et al. A PD-L1-targeted probody™ therapeutic provides anti-tumor efficacy while minimizing induction of systemic autoimmunity in preclinical studies. Cancer Immunol Res. 2016;4(1Suppl):Abstractnr A081. Available from: https://cytomx.com/wp-content/uploads/20150911-PDL1-poster-FINALforPRINT.pdf
- Giesen D, Broer LN, Lub-De Hooge MN, et al. 89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors. Ann Oncol. 2019 Feb 1;30(Supplement_1):80.
- Tipton KA, Wong KR, Singson V, et al. Probody™ therapeutic targeting PD-1 provides preclinical anti-tumor efficacy while minimizing induction of autoimmunity as a single agent and in combination with CTLA-4 blockade. J Immunother Cancer. 2016;4(Suppl1):P213. Available from: https://cytomx.com/wp-content/uploads/SITC-2016-PD1-FINAL.pdf
- Price KD, Simutis F, Fletcher A, et al. Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys. Mol Cancer Ther. 2018;17(1Suppl):AbstractLB–B33.
- Lyon R. Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discov Today Technol. 2018 Dec;30:105–109.
- Lin J, Sagert S. Targeting drug conjugates to the tumor microenvironment: probody drug conjugates. In: Damelin M, editor. Innovations for next-generation antibody-drug conjugates. Cham, Switzerland: Springer International Publishing AG; 2018. p. 281–298.
- Weaver AY, Singh S, DuPage A, et al. Development of a probody drug conjugate (PDC) against CD166 for the treatment of multiple cancers. Mol Cancer Ther. 2015;14(12Suppl 2):AbstractC165. Available from: https://cytomx.com/wp-content/uploads/20151104_CD166_AACR_NCI_EORTC_poster_TO_PRINT_FINAL.pdf
- Singh S, DuPage A, Weaver AY, et al. Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas. Cancer Res. 2016;76(14 Supplement):Abstract 2975. Available from: https://cytomx.com/wp-content/uploads/Preclinical-Development-of-a-ProbodyTM-Drug-Conjugate-PDC-Targeting-CD71-for-the-Treatment-of-Multiple-Cancers-AACR-2016.pdf
- Lutterbuese R, Raum T, Kischel R, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605–12610.
- Boustany LM, La Porte SL, Wong L, et al. EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies. Mol Cancer Ther. 2018;17(1Suppl):AbstractA164. Available from: https://cytomx.com/wp-content/uploads/CytomX-PbTCB_AACR_NCI_EORTC_2017_FINAL.pdf
- Lyman SK, Gordon J, DuPage A, et al. Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2 trial. J Immunother Cancer. 2018;6(Suppl1):114, P87. Available from: https://cytomx.com/wp-content/uploads/150105031-03_SITC_L1k.pdf.
- Naing A, Thistlethwaite F, Spira A, et al. CX-072, a PD-L1 probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072. J Clin Oncol. 2019;3715_suppl:abstract 2513. Available from: https://cytomx.com/wp-content/uploads/ASCO-2019-Monotherapy-Preliminary-Results-PROCLAIM-CX-072.pdf
- Plummer R, Sanborn RE, de Vries E, et al. Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab in patients with advanced solid tumors. Ann Oncol. 2018;29(suppl_8):viii133–viii148. Available from: https://cytomx.com/wp-content/uploads/Plummer_et_al_ESMO_Poster.pdf
- Meric-Bernstam F, Boni V, Spira A, et al. Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the probody™ drug conjugate CX-2009 in patients with advanced solid tumors. Cancer Res. 2019;79(13 Supplement):LB–185. Available from: https://cytomx.com/wp-content/uploads/AACR-2019-PROCLAIM-CX-2009_Preliminary-Results_HI-RES.pdf
- PROTIA (T-cell engager) [Internet]. [ cited 2019 June 26]. Available from: https://www.amunix.com/technology/pro-tia/
- Trang VH, Zhang X, Yumul RC, et al. A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol. 2019 May 27;37(7):761–765.
- Lin SJ, Dayao MR, Kim KJ, et al. ProTriTAC: A protease-activatable T cell engager platform that links half-life extension to functional masking. J Immunother Cancer. 2018;6(Suppl1):115, P608. Available from: https://www.harpoontx.com/file.cfm/43/docs/SITC_2018_ProTriTAC_Poster.pdf
- Dettling D, Kwok E, Quach L, et al. COBRA: A novel conditionally active bispecifıc antibody that regresses established solid tumors in mice. Cancer Res. 2019;79(13Suppl):Abstractnr 557. Available from: https://cancerres.aacrjournals.org/content/79/13_Supplement/557
- Metz S, Panke C, Haas AK, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel. 2012 Oct;25(10):571–580.
- Onuoha SC, Ferrari M, Sblattero D, et al. Rational design of antirheumatic prodrugs specific for sites of inflammation. Arthritis Rheumatol. 2015 Oct;67(10):2661–2672.
- Pai CS, Simons DM, Lu X, et al. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 Jan 2;129(1):349–363.
- Preyer M, Weinstein P, Aliperta R, et al. T cell engaging antibody circuit (TEACs): the next generation of T cell engaging bispecific prodrugs [Internet]. [cited 2019 Nov]. Available from: http://revitope.com/dist/pdf/180321-GRCposter.pdf
- Lu Y-C, Chuang C-H, Chuang K-H, et al. Specific activation of proInfliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol. 2019;17(6):e3000286. .
- Chen IJ, Chuang CH, Hsieh YC, et al. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017 Sep 14;7(1):11587.
- Yang Y, Guo Q, Xia M, et al. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs. 2015;7(2):440–450.
- Yang Y, Guo Q, Chen X, et al. Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. MAbs. 2016;8(2):405–413.
- Han X, Bryson PD, Zhao Y, et al. Masked Chimeric antigen receptor for tumor-specific activation. Mol Ther. 2017 Jan 4;25(1):274–284.
- Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018 Jan 1;4(1):98–101.
- Mancek-Keber M. Inflammation-mediating proteases: structure, function in (patho) physiology and inhibition. Protein Pept Lett. 2014;21(12):1209–1229.
- Ten Cate H, Hackeng TM, Garcia de Frutos P. Coagulation factor and protease pathways in thrombosis and cardiovascular disease. Thromb Haemost. 2017 Jun 28;117(7):1265–1271.
- Tokito A, Jougasaki M. Matrix metalloproteinases in non-neoplastic disorders. Int J Mol Sci. 2016 Jul 21;17(7):1178.
- Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019 Feb 15;20(4):840.
- Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016 Jul;68(3):701–787.
- Liu R, Li X, Xiao W, et al. Tumor-targeting peptides from combinatorial libraries. Adv Drug Deliv Rev. 2017 Feb;110–111:13–37.
- He X, Li J, An S, et al. pH-sensitive drug-delivery systems for tumor targeting. Ther Deliv. 2013 Dec;4(12):1499–1510.
- Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011 Jul 18;63(8):659–670.
- Navya PN, Kaphle A, Srinivas SP, et al. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019 Jul 15;6(1):23.